Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20

Key Points

• Analyst sentiment is moderately bullish: Seven analysts give Pulse Biosciences a consensus “Moderate Buy” rating, with an average 12-month price target of $50.20; targets range as high as $70.
• Institutional ownership is substantial: Institutional investors hold 76.95% of the company, while insiders own 74%; insiders purchased about $199,931 of shares over the past three months.
• Financial results remain weak despite strong share performance: The stock opened at $50.50 and has climbed sharply from its 52-week low of $12.56, but the latest quarter missed EPS and revenue estimates, with analysts forecasting a full-year loss of $1.29 per share.

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $50.20.

A number of equities research analysts have recently weighed in on PLSE shares. Wall Street Zen upgraded shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, September 6th. Canaccord Genuity Group increased their price target on Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a report on Friday, July 17th. Oppenheimer restated an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, BTIG Research began coverage on shares of Pulse Biosciences in a report on Wednesday, September 23rd. They set a "buy" rating and a $70.00 price target for the company.

Insider Buying and Selling

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,036 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the purchase, the chief operating officer directly owned 1,036 shares of the company's stock, valued at approximately $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have purchased 4,095 shares of company stock worth $199,931 in the last three months. 74.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth $40,672,000. Bank of America Corp DE acquired a new position in Pulse Biosciences during the second quarter worth about $40,115,000. Panoramic Capital LLC acquired a new position in Pulse Biosciences during the second quarter worth about $2,719,000. Bank of New York Mellon Corp bought a new position in shares of Pulse Biosciences in the second quarter worth about $1,196,000. Finally, Formula Growth Ltd. bought a new position in shares of Pulse Biosciences in the second quarter worth about $832,000. Institutional investors own 76.95% of the company's stock.

Pulse Biosciences Price Performance

PLSE opened at $50.50 on Tuesday. The business has a fifty day simple moving average of $47.71 and a 200 day simple moving average of $32.69. The company has a market capitalization of $3.58 billion, a PE ratio of -42.80 and a beta of 1.57. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Equities analysts anticipate that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

About Pulse Biosciences

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company's lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.